Developer docs
API playgroundTry for free, no card

Search company profiles

IKEDA MOHANDO

Full company profile

uuid000msfc

Namestring
IKEDA MOHANDO
Legal namestring
株式会社池田模範堂
Company typeenum
Private
Founded yearint
1926
Descriptiontext

IKEDA MOHANDO Co., Ltd. (株式会社池田模範堂) is a privately held Japanese over-the-counter (OTC) pharmaceutical manufacturer headquartered in Kamiichi, Toyama Prefecture, with regional offices in Tokyo, Nagoya, Osaka, and Fukuoka. The company specializes in dermatology and pediatric symptom relief, with its flagship 'MUHI' (ムヒ) brand of topical anti-itch and insect bite remedies dating to 1926 and approaching its 100-year anniversary in 2026. Its product portfolio spans topical creams, liquids, and patches for itching, eczema, chilblains, athlete's foot, scalp conditions, and wound care; oral itch tablets (Muhi AZ) and dermatology-specific launches such as Muhi ER (ear itching, April 2020) and Muhi Beta V Liquid (stubborn eczema/dermatitis, 2026); an Anpanman-branded pediatric line of cold syrups and wound care; Hibicare crack/chapping ointments; Asemuhi EX for sweat rash; Delicare for intimate-area itching; and the Ibikist anti-snoring product.

Underlying technical capability rests on proprietary topical OTC formulations and a dedicated MUHI Skin Research Center, supported by structured R&D output (publications, conference presentations, an internal Ikeda Mohando Award) and house IP covering formulation, dosage form (cream, liquid, patch, tablet, hydrocolloid pad), and indication targeting. The company also operates an extensive consumer-education library ('Skin Trouble Information' (肌トラブル情報館), baby/child skin care guides, insect bite information (虫さされ情報館), and itch-mechanism manga) that functions as a top-of-funnel content asset.

The business model is B2C mass-market OTC drug sales in Japan. Revenue is generated primarily through physical retail distribution via pharmacies and drugstores (with dedicated partner support pages and downloadable catalogs for retail staff), an official online store (shop.ikedamohando.co.jp), and other domestic online retailers. Commercial reach is augmented by TV advertising, celebrity endorsements (notably Number_i members), cross-IP collaborations (Pokemuhi), and event-based 100th-anniversary promotions. The customer base is segmented horizontally into general consumers with skin conditions and parents/caregivers of children seeking OTC pediatric symptom relief, with no disclosed enterprise, B2B, or institutional customer concentration.

Short descriptiontext

IKEDA MOHANDO is a privately held Japanese OTC pharmaceutical manufacturer that develops, produces, and sells dermatological, pediatric, and itch-relief products under the century-old MUHI brand to Japanese consumers via pharmacies, drugstores, and online retail.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersKamiichi, Japan
HQ citystring
Kamiichi
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
OTC pharmaceutical products, dermatological skin care, insect bite remedies, children's cold medicines, wound care products
Industry2 codes
PRIMARYHLAIADAE
Dermatology & Topical Skin Treatments
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAL
Pediatric OTC Medicines
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics2840
Product category
OTC Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1OTC Pharmaceutical Product Sales
TypeHardware Sales
Description

Ikeda Mohando generates revenue through the manufacture and sale of over-the-counter pharmaceutical products for skin conditions, including insect bite treatments, anti-itch medications, cold medicines for children, and wound care products. Products are sold through retail pharmacies, drugstores, and the company's official online store.

ikedamohando.co.jp
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IKEDA MOHANDO manufactures and markets over-the-counter pharmaceutical products for skin conditions, including the long-selling MUHI brand of insect bite and anti-itch topical remedies, scalp and eczema treatments, children's cold and syrup medications, and wound care products. The company sells these products primarily through pharmacies, drugstores, and its own online shop in Japan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Muhi ER product launched April 2020 for ear itching conditions
+1 more record
Product overview1 text field

IKEDA MOHANDO is a Japanese pharmaceutical company that manufactures and sells OTC (over-the-counter) medications and skincare products. The company operates under the core Muhi (ムヒ) brand, which has been providing insect bite and itch remedies for over 100 years. Their product portfolio consists of multiple product lines: the Muhi insect bite/itch series (ムヒシリーズ), the Anpanman-themed children's series (ムヒのアンパンマンシリーズ), the Hibicare crack/heal series (ヒビケアシリーズ), Muhi ER for ear itching, Muhi Beta V liquid for eczema/dermatitis, Asemuhi EX for sweat rash, Muhi AZ tablets for oral itch relief, Muhi HD for scalp conditions, Delicare for intimate area care, Muhi Soft GX for severe itching, and cold remedies for children. The products range from topical ointments, liquids, patches, and tablets to hydrocolloid wound care products. The company also maintains research and development operations through the MUHI Skin Research Center.

Product and service17 records
1Muhi S (ムヒS)
CategoryTopical anti-itch and insect bite remedy
Description

Long-selling topical itch and insect bite remedy cream for general consumers.

2Muhi ER (ムヒER)
CategoryAnti-itch product for ear conditions
Description

Anti-itch product specifically formulated for ear itching, particularly for hay fever sufferers, launched April 2020.

3Muhi Beta V Liquid (ムヒベタV液)
CategoryEczema and dermatitis treatment
Description

Topical liquid for stubborn eczema, dermatitis, and persistent itching.

4Muhi AZ Tablets (ムヒAZ錠)
CategoryOral itch relief medication
Description

Oral itch medication providing 12-hour lasting relief from itching.

5Muhi HD Series (ムヒHDシリーズ)
CategoryScalp itch and eczema treatment
Description

Topical treatments for scalp itchiness and eczema, including standard and sting-free (HDm) formulations.

6Muhi Alpha EX (ムヒアルファEX)
CategorySevere insect bite and itch treatment
Description

Topical treatment for severe, unbearable insect bites and itching, available in liquid and cream formulations.

7Muhi Patch A1 (ムヒパッチA1)
CategoryAdhesive anti-itch patch
Description

Adhesive patch-style anti-itch treatment for insect bites that prevents scratching, available in 38 and 76 sheet packages.

8Muhi Soft GX Series (ムヒソフトGXシリーズ)
CategoryTreatment for severe skin itching
Description

Topical treatment for severe itching skin, available in cream and emulsion formulations.

9Muhi Baby (ムヒ・ベビーb / 液体ムヒベビー)
CategoryPediatric itch remedy
Description

Long-selling infant- and child-appropriate itch remedy cream and liquid formulations.

10Hibicare Ointment b (ヒビケア軟膏b)
CategoryCrack and chapping treatment
Description

Medicinal ointment for treating painful finger and hand cracks and chapping.

11Hibicare FT (ヒビケアFT)
CategoryHeel crack repair ointment
Description

Medicinal ointment specifically for heel cracks, utilizing pharmaceutical repair properties.

12Asemuhi EX Series (アセムヒEXシリーズ)
CategorySweat rash treatment
Description

Topical treatment for sweat-induced rash and itching, available in cream and liquid formulations.

13Muhi Children's Cold Syrup series (ムヒのこどもかぜシロップシリーズ)
CategoryPediatric cold medications
Description

Anpanman-branded children's cold medications including cough syrup, cold syrup, rhinitis syrup, and cold granules.

14Muhi Wound Tape / Pad / Liquid (ムヒのキズテープ/パッド/きず液)
CategoryPediatric wound care
Description

Anpanman-branded wound care products including adhesive tapes, hydrocolloid pads, and sting-free antiseptic liquid.

15Odecure EX (オデキュアEX)
CategoryBoil and skin abscess treatment
Description

Fast-acting treatment for painful boils and skin abscesses.

16Delicare series (デリケアシリーズ)
CategoryIntimate area care
Description

Products for intimate area itching and irritation, including men's (Delicare Mz) and general formulations.

17Ibikist (イビキスト)
CategoryAnti-snoring product
Description

Swedish-origin anti-snoring product used before bedtime as a new etiquette product.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Ministry of Health, Labour and Welfare (厚生労働省)
Strategic tierMinorTypeOthers
Description

Listed as a related organization link on Ikeda Mohando's website, indicating institutional connection to government health regulatory body.

ikedamohando.co.jp
Strategic tierMinorTypeOthers
Description

Listed as a related organization link indicating academic/professional society affiliation.

3Japan Dermatological Association (日本皮膚科学会)
Strategic tierMinorTypeOthers
Description

Listed as a related organization link indicating professional association connection in dermatology field.

ikedamohando.co.jp
4Japan Federation of Self-Medication Industries (日本一般用医薬品連合会)
Strategic tierMinorTypeOthers
Description

Listed as related organization. Focuses on proper handling of OTC medicine seals.

ikedamohando.co.jp
5Japan OTC Medicines Association (日本OTC医薬品協会)
Strategic tierMinorTypeOthers
Description

Listed as related organization providing drug education materials for elementary through high school students.

ikedamohando.co.jp
6Toyama Drug Discovery Consortium (くすりのシリコンバレーTOYAMA創造コンソーシアム)
Strategic tierMinorTypeOthers
Description

Listed as related organization representing regional pharmaceutical industry consortium in Toyama.

ikedamohando.co.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Kobayashi Pharmaceutical
TypeDirect peer
Description

Japanese consumer healthcare leader with products including skincare, dermatology remedies, and household health items. Comparable OTC business model, Japanese pharmacy/drugstore distribution, and brand-driven marketing approach.

2Rohto Pharmaceutical
TypeDirect peer
Description

Japanese OTC and consumer healthcare company with strong dermatology and eye-care franchises (Mentholatum, Rohto Eye). Direct competitor in OTC skin care with overlapping product formats (creams, ointments, patches) and Japanese retail distribution.

3Sato Pharmaceutical
TypeDirect peer
Description

Long-established Japanese OTC pharmaceutical company with brands like Stona and Yunker. Directly comparable in scale, channel footprint (pharmacies/drugstores), and focus on dermatology and household remedy categories.

4Pola Orbis Holdings
TypeBroad incumbent
Description

Japanese skincare and cosmetics holding company with dermatology-adjacent consumer brands. Operates in adjacent skincare category through different retail channels (department stores, beauty specialty), making it a partial comparable for premium Japanese skin care positioning.

TypeEmerging player
Description

Japanese men's grooming and personal care company with selected dermatology positioning. Less direct overlap with Ikeda Mohando's core itch franchise but competes in adjacent male skin care categories through similar drugstore distribution.

TypeDirect peer
Description

Japanese household and personal care manufacturer with itch-relief and insect repellent products. Competes with Ikeda Mohando's discontinued Musipale line and broader dermatology/insect bite categories in drugstores.

7Daiichi Sankyo Healthcare
TypeDirect peer
Description

OTC subsidiary of Daiichi Sankyo operating brands such as Loxonin S and Transino. Competes head-to-head with Ikeda Mohando in Japanese drugstores, with comparable dermatology and pain relief offerings distributed through identical retail channels.

8Taisho Pharmaceutical
TypeDirect peer
Description

One of Japan's largest OTC pharmaceutical companies, marketing brands like Lipovitan and a broad dermatology/consumer health portfolio. Direct competitor in Japanese OTC retail channels, overlapping with Ikeda Mohando's pharmacy distribution model and similar dermatology product positioning.

TypeDirect peer
Description

Mid-sized Japanese OTC pharmaceutical firm with brands across dermatology, pain relief, and consumer health. Similar mid-tier position, pharmacy/drugstore distribution, and dermatology product overlap with Ikeda Mohando's portfolio.

10Lion Corporation
TypeBroad incumbent
Description

Large Japanese consumer products company spanning oral care, household cleaners, and select OTC pharmaceuticals. Broader portfolio than Ikeda Mohando but competes in overlapping personal care categories through the same retail channels.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IKEDA MOHANDO

OTC Pharmaceuticalsikedamohando.co.jp

IKEDA MOHANDO is a privately held Japanese OTC pharmaceutical manufacturer that develops, produces, and sells dermatological, pediatric, and itch-relief products under the century-old MUHI brand to Japanese consumers via pharmacies, drugstores, and online retail.

What IKEDA MOHANDO does

IKEDA MOHANDO Co., Ltd. (株式会社池田模範堂) is a privately held Japanese over-the-counter (OTC) pharmaceutical manufacturer headquartered in Kamiichi, Toyama Prefecture, with regional offices in Tokyo, Nagoya, Osaka, and Fukuoka. The company specializes in dermatology and pediatric symptom relief, with its flagship 'MUHI' (ムヒ) brand of topical anti-itch and insect bite remedies dating to 1926 and approaching its 100-year anniversary in 2026. Its product portfolio spans topical creams, liquids, and patches for itching, eczema, chilblains, athlete's foot, scalp conditions, and wound care; oral itch tablets (Muhi AZ) and dermatology-specific launches such as Muhi ER (ear itching, April 2020) and Muhi Beta V Liquid (stubborn eczema/dermatitis, 2026); an Anpanman-branded pediatric line of cold syrups and wound care; Hibicare crack/chapping ointments; Asemuhi EX for sweat rash; Delicare for intimate-area itching; and the Ibikist anti-snoring product.

Underlying technical capability rests on proprietary topical OTC formulations and a dedicated MUHI Skin Research Center, supported by structured R&D output (publications, conference presentations, an internal Ikeda Mohando Award) and house IP covering formulation, dosage form (cream, liquid, patch, tablet, hydrocolloid pad), and indication targeting. The company also operates an extensive consumer-education library ('Skin Trouble Information' (肌トラブル情報館), baby/child skin care guides, insect bite information (虫さされ情報館), and itch-mechanism manga) that functions as a top-of-funnel content asset.

The business model is B2C mass-market OTC drug sales in Japan. Revenue is generated primarily through physical retail distribution via pharmacies and drugstores (with dedicated partner support pages and downloadable catalogs for retail staff), an official online store (shop.ikedamohando.co.jp), and other domestic online retailers. Commercial reach is augmented by TV advertising, celebrity endorsements (notably Number_i members), cross-IP collaborations (Pokemuhi), and event-based 100th-anniversary promotions. The customer base is segmented horizontally into general consumers with skin conditions and parents/caregivers of children seeking OTC pediatric symptom relief, with no disclosed enterprise, B2B, or institutional customer concentration.

IKEDA MOHANDO firmographics

Firmographics
Name
IKEDA MOHANDO
Legal name
株式会社池田模範堂
Website
https://ikedamohando.co.jp
Company type
Private
Founded year
1926
Operating status
Operating
Headcount range
251–500 employees
Short description
IKEDA MOHANDO is a privately held Japanese OTC pharmaceutical manufacturer that develops, produces, and sells dermatological, pediatric, and itch-relief products under the century-old MUHI brand to Japanese consumers via pharmacies, drugstores, and online retail.
Ownership category
akta.pro rank

IKEDA MOHANDO industry classification

Industry
Product category
OTC Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)
akta.pro industry
PRIMARYHLAIADAE
Dermatology & Topical Skin Treatments
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAL
Pediatric OTC Medicines
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • OTC pharmaceutical products
  • Dermatological skin care
  • Insect bite remedies
  • Children's cold medicines
  • Wound care products

Where IKEDA MOHANDO is headquartered

Location

Headquarters

HQ city
Kamiichi
HQ country
Japan
HQ region
Asia

Offices5 records

Markets served

IKEDA MOHANDO business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. OTC Pharmaceutical Product Sales: Ikeda Mohando generates revenue through the manufacture and sale of over-the-counter pharmaceutical products for skin conditions, including insect bite treatments, anti-itch medications, cold medicines for children, and wound care products. Products are sold through retail pharmacies, drugstores, and the company's official online store.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

IKEDA MOHANDO product offering

Product offering

Core offering

IKEDA MOHANDO manufactures and markets over-the-counter pharmaceutical products for skin conditions, including the long-selling MUHI brand of insect bite and anti-itch topical remedies, scalp and eczema treatments, children's cold and syrup medications, and wound care products. The company sells these products primarily through pharmacies, drugstores, and its own online shop in Japan.

Product overview

IKEDA MOHANDO is a Japanese pharmaceutical company that manufactures and sells OTC (over-the-counter) medications and skincare products. The company operates under the core Muhi (ムヒ) brand, which has been providing insect bite and itch remedies for over 100 years. Their product portfolio consists of multiple product lines: the Muhi insect bite/itch series (ムヒシリーズ), the Anpanman-themed children's series (ムヒのアンパンマンシリーズ), the Hibicare crack/heal series (ヒビケアシリーズ), Muhi ER for ear itching, Muhi Beta V liquid for eczema/dermatitis, Asemuhi EX for sweat rash, Muhi AZ tablets for oral itch relief, Muhi HD for scalp conditions, Delicare for intimate area care, Muhi Soft GX for severe itching, and cold remedies for children. The products range from topical ointments, liquids, patches, and tablets to hydrocolloid wound care products. The company also maintains research and development operations through the MUHI Skin Research Center.

Differentiator

Problem solved

Functional benefit

Products and services

  • Muhi S (ムヒS) Long-selling topical itch and insect bite remedy cream for general consumers.
  • Muhi ER (ムヒER) Anti-itch product specifically formulated for ear itching, particularly for hay fever sufferers, launched April 2020.
  • Muhi Beta V Liquid (ムヒベタV液) Topical liquid for stubborn eczema, dermatitis, and persistent itching.
  • Muhi AZ Tablets (ムヒAZ錠) Oral itch medication providing 12-hour lasting relief from itching.
  • Muhi HD Series (ムヒHDシリーズ) Topical treatments for scalp itchiness and eczema, including standard and sting-free (HDm) formulations.
  • Muhi Alpha EX (ムヒアルファEX) Topical treatment for severe, unbearable insect bites and itching, available in liquid and cream formulations.
  • Muhi Patch A1 (ムヒパッチA1) Adhesive patch-style anti-itch treatment for insect bites that prevents scratching, available in 38 and 76 sheet packages.
  • Muhi Soft GX Series (ムヒソフトGXシリーズ) Topical treatment for severe itching skin, available in cream and emulsion formulations.
  • Muhi Baby (ムヒ・ベビーb / 液体ムヒベビー) Long-selling infant- and child-appropriate itch remedy cream and liquid formulations.
  • Hibicare Ointment b (ヒビケア軟膏b) Medicinal ointment for treating painful finger and hand cracks and chapping.
  • Hibicare FT (ヒビケアFT) Medicinal ointment specifically for heel cracks, utilizing pharmaceutical repair properties.
  • Asemuhi EX Series (アセムヒEXシリーズ) Topical treatment for sweat-induced rash and itching, available in cream and liquid formulations.
  • Muhi Children's Cold Syrup series (ムヒのこどもかぜシロップシリーズ) Anpanman-branded children's cold medications including cough syrup, cold syrup, rhinitis syrup, and cold granules.
  • Muhi Wound Tape / Pad / Liquid (ムヒのキズテープ/パッド/きず液) Anpanman-branded wound care products including adhesive tapes, hydrocolloid pads, and sting-free antiseptic liquid.
  • Odecure EX (オデキュアEX) Fast-acting treatment for painful boils and skin abscesses.
  • Delicare series (デリケアシリーズ) Products for intimate area itching and irritation, including men's (Delicare Mz) and general formulations.
  • Ibikist (イビキスト) Swedish-origin anti-snoring product used before bedtime as a new etiquette product.

Quantifiable outcome

  • Muhi ER product launched April 2020 for ear itching conditions
  • +1 more outcomes

Companies that use IKEDA MOHANDO

Customer profile

Segments2 records

Ideal customer profiles2 records

IKEDA MOHANDO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

IKEDA MOHANDO partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor.

  • Ministry of Health, Labour and Welfare (厚生労働省)minorOthersListed as a related organization link on Ikeda Mohando's website, indicating institutional connection to government health regulatory body.
  • Japan Pharmaceutical Society (日本薬学会)minorOthersListed as a related organization link indicating academic/professional society affiliation.
  • Japan Dermatological Association (日本皮膚科学会)minorOthersListed as a related organization link indicating professional association connection in dermatology field.
  • Japan Federation of Self-Medication Industries (日本一般用医薬品連合会)minorOthersListed as related organization. Focuses on proper handling of OTC medicine seals.
  • Japan OTC Medicines Association (日本OTC医薬品協会)minorOthersListed as related organization providing drug education materials for elementary through high school students.
  • Toyama Drug Discovery Consortium (くすりのシリコンバレーTOYAMA創造コンソーシアム)minorOthersListed as related organization representing regional pharmaceutical industry consortium in Toyama.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

IKEDA MOHANDO competitors and assessment

Company assessment

Direct peers

  • Kobayashi Pharmaceutical: Japanese consumer healthcare leader with products including skincare, dermatology remedies, and household health items. Comparable OTC business model, Japanese pharmacy/drugstore distribution, and brand-driven marketing approach.
  • Rohto Pharmaceutical: Japanese OTC and consumer healthcare company with strong dermatology and eye-care franchises (Mentholatum, Rohto Eye). Direct competitor in OTC skin care with overlapping product formats (creams, ointments, patches) and Japanese retail distribution.
  • Sato Pharmaceutical: Long-established Japanese OTC pharmaceutical company with brands like Stona and Yunker. Directly comparable in scale, channel footprint (pharmacies/drugstores), and focus on dermatology and household remedy categories.
  • Earth Corporation: Japanese household and personal care manufacturer with itch-relief and insect repellent products. Competes with Ikeda Mohando's discontinued Musipale line and broader dermatology/insect bite categories in drugstores.
  • Daiichi Sankyo Healthcare: OTC subsidiary of Daiichi Sankyo operating brands such as Loxonin S and Transino. Competes head-to-head with Ikeda Mohando in Japanese drugstores, with comparable dermatology and pain relief offerings distributed through identical retail channels.
  • Taisho Pharmaceutical: One of Japan's largest OTC pharmaceutical companies, marketing brands like Lipovitan and a broad dermatology/consumer health portfolio. Direct competitor in Japanese OTC retail channels, overlapping with Ikeda Mohando's pharmacy distribution model and similar dermatology product positioning.
  • Kowa Pharmaceutical: Mid-sized Japanese OTC pharmaceutical firm with brands across dermatology, pain relief, and consumer health. Similar mid-tier position, pharmacy/drugstore distribution, and dermatology product overlap with Ikeda Mohando's portfolio.

Broad incumbents

  • Pola Orbis Holdings: Japanese skincare and cosmetics holding company with dermatology-adjacent consumer brands. Operates in adjacent skincare category through different retail channels (department stores, beauty specialty), making it a partial comparable for premium Japanese skin care positioning.
  • Lion Corporation: Large Japanese consumer products company spanning oral care, household cleaners, and select OTC pharmaceuticals. Broader portfolio than Ikeda Mohando but competes in overlapping personal care categories through the same retail channels.

Emerging players

  • Mandom Corporation: Japanese men's grooming and personal care company with selected dermatology positioning. Less direct overlap with Ikeda Mohando's core itch franchise but competes in adjacent male skin care categories through similar drugstore distribution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

IKEDA MOHANDO social profiles

Digital presence

IKEDA MOHANDO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IKEDA MOHANDO leadership team

Management profile

Number of profiles

Profiles1 record

IKEDA MOHANDO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IKEDA MOHANDO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IKEDA MOHANDO

What does IKEDA MOHANDO do?

IKEDA MOHANDO manufactures and markets over-the-counter pharmaceutical products for skin conditions, including the long-selling MUHI brand of insect bite and anti-itch topical remedies, scalp and eczema treatments, children's cold and syrup medications, and wound care products. The company sells these products primarily through pharmacies, drugstores, and its own online shop in Japan.

Is IKEDA MOHANDO a public or private company?

IKEDA MOHANDO is a private company. It is classified as family owned and is currently operating.

When was IKEDA MOHANDO founded?

IKEDA MOHANDO was founded in 1926. It employs 251 to 500 people.

Where is IKEDA MOHANDO based?

IKEDA MOHANDO is headquartered in Kamiichi, Japan, in the Asia region.

How does IKEDA MOHANDO make money?

One revenue line is on record: OTC Pharmaceutical Product Sales.

Who are IKEDA MOHANDO's main competitors?

Direct peers on record are Kobayashi Pharmaceutical, Rohto Pharmaceutical, Sato Pharmaceutical, Earth Corporation, Daiichi Sankyo Healthcare, Taisho Pharmaceutical and Kowa Pharmaceutical. Broad incumbents are Pola Orbis Holdings and Lion Corporation. Mandom Corporation is listed as an emerging player.

Does IKEDA MOHANDO have an API?

No public API is recorded for IKEDA MOHANDO.

What industry is IKEDA MOHANDO in?

IKEDA MOHANDO's product category is OTC Pharmaceuticals. Its primary akta.pro industry code is HLAIADAE, Dermatology & Topical Skin Treatments, with a secondary code of HLAIADAL, Pediatric OTC Medicines. Its NAICS code is 32541 and its SIC code is 2840.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesWe support various ways of 'communicating'! A new habit for your throat and voice! New product 'Nodoment' released.Ikeda Mohando Co., Ltd. will sell Nodamente, a throat spray for voice support, from August 17, 2026. The 25g product costs 1,620 yen and is based on a survey showing over half of voice users want to improve throat condition.Japan TodayMuhi cream sets Guinness record as longest-selling anti-itch productJapanese anti-itch medicine Muhi cream has been recognized by Guinness World Records as the longest-selling over-the-counter bite and sting anti-itch product, marking 100 years since its 1926 launch. The official certificate was presented to Ikeda Mohando Co. president Katsuhiro Ikeda at an event in Toyama Prefecture, central Japan, where he pledged to continue producing products worthy of the brand name. The original petroleum jelly ointment was developed for sericulture industry workers who suffered insect bites while avoiding insecticides to protect silkworms.PrtimesFor the first time in history! A theme park for the groin has opened in Omotesando. The experiential exhibition 'Omatārando' that faces the groin opens today! The opening event features 'Haru to Hikōki', known for 'Bakido', as the groin navigator!The experiential exhibition 'Omatārando' opens July 10-12 at STUMP BASE in Minato-ku, Tokyo, with 'Haru to Hikōki' as the groin navigator. Admission is free, though numbered tickets may be issued during busy times.PrtimesA hundred years of "thank you" packed into a fine product from Toyama. The 100th anniversary of "Muhi" - the "Muhi 100th Birthday Festival" - has unveiled 17 collaborative products with 8 companies in Toyama Prefecture.Ikeda Mohando Co., Ltd. will announce 17 collaboration products with eight Toyama companies for its Muhi 100th anniversary festival on July 25-26, 2026. The items include kamaboko, curry, bath products, socks, cider, wind chimes, and sake, sold at linked venues and as capsule prizes.PrtimesFor the first time in history! A theme park for the groin has opened in Omotesando. The experiential exhibition 'Omataraland' will open on July 10 (Friday)! 15 types of exhibits will be featured, including the 'Immersive Pants' that allow you to experience the feelings of the groin during summer.Delicare M's will open the groin-themed exhibition 'Omatara Land' at Omotesando STUMP BASE from July 10-12, 2026, featuring 15 exhibits including 'Immersive Pants' and 'Omatalk'. The comedy duo Haru to Hikoki will serve as guides, and the event is free to attend.PrtimesJune 1st is "Muhi Day". A commemorative event celebrating the 100th anniversary of the release of "Muhi" will be held in the night sky of Toyama, announcing lanterns, fireworks, and stage performers.Ikeda Mohando Co., Ltd. will hold the Muhi 100th Birthday Festival in Toyama on July 25-26, 2026, celebrating the 100th anniversary of its anti-itch medicine Muhi. The event includes a participatory lantern night on July 25 and a synchronized fireworks show on July 26, with stage performers to be announced.PrtimesIkeda Mohando, celebrating the 100th anniversary of 'Muhi', has introduced the generative AI-based knowledge management system 'STiV'.Fanlead Inc. announced that its generative AI-based knowledge management system STiV is fully operational at Ikeda Mohando's Reliability Assurance Department. The implementation cut business hours by 50% through OCR digitization of handwritten documents, reducing reading and report-drafting time from one hour to about 30 minutes. Fanlead will continue supporting system integration and updating STiV's functions.Prtimes[Survey on Ear Conditions of Hay Fever Patients] That itch might actually be 'pollen ear'? 1 in 4 people suffer from hay fever, and 44.2% of them may worsen their condition due to incorrect responses like excessive ear scratching.Ikeda Mohando Co., Ltd. conducted a survey on ear itching conditions among 1,000 men and women aged 20 to 69 nationwide in Japan who suffer from hay fever, conducted February 3-5, 2026. The survey found that approximately 1 in 4 hay fever patients experience ear itching as a symptom, with over 40% of these individuals reporting that their ears itch more on high pollen days, and 44.2% potentially worsening their condition through incorrect responses such as excessive ear scratching with cotton swabs or ear picks. The company is using the survey findings to promote its anti-itch product Muhi ER, which was launched in April 2020.